As shown in Fig. 2-a, although refametinib and pictilisib treatments caused a dose-dependent cell growth inhibition in all colon cancer cell lines, the HER2-amplified cells were more sensitive to both drugs, as single agents, compared to parental cells at all concentrations tested. This evidence concerns the gene ERBB2 and malignant colon neoplasm.